Indo US Bio-Tech Limited has announced the resignation of Mrs. Nehaben Sachinbhai Patel from her position as Non-Executive Independent Director, effective April 21, 2026. The company informed both BSE and NSE about this development on April 22, 2026, in compliance with regulatory disclosure requirements.

Director Resignation Details

Mrs. Nehaben Sachinbhai Patel, holding Director Identification Number (DIN) 09263180, submitted her resignation letter dated April 21, 2026, citing personal and unavoidable reasons for her departure from the board.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made pursuant to Para A of Part A of Schedule III to the said Regulations and applicable SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Director's Confirmation

Mrs. Patel has provided written confirmation that there are no other material reasons for her resignation beyond those stated in her resignation letter. Additionally, she has confirmed that she does not hold directorship in any other listed entity.

Company Response

The resignation was processed with immediate effect from April 21, 2026. The company has received all necessary confirmations and documentation related to the resignation, ensuring compliance with regulatory requirements. Indo US Bio-Tech Limited acknowledged Mrs. Patel's contribution during her tenure as an Independent Director on the board.

Indo us bio-tech Limited has submitted its mandatory compliance certificate under SEBI regulations for the financial year 2026. The company filed the certificate with stock exchanges on April 6, 2026, maintaining its regulatory compliance obligations.

SEBI Compliance Certificate Details

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the year ended March 31, 2026. Bigshare Services Private Limited, serving as the company's registrar and share transfer agent, issued the compliance certificate dated March 31, 2026.

Certificate Confirmation

The registrar confirmed that no securities were received from depository participants for dematerialization up to March 31, 2026. Consequently, no certificates were mutilated and cancelled during this period, and there was no substitution of depositories' names in the register of members as registered owners within the stipulated 15-day timeframe.

Stock Exchange Submission

Indo Us Bio-Tech Limited submitted the certificate to both major Indian stock exchanges where its shares are listed. The company secretary and compliance officer, Ms. Dimpy Joshi, signed the submission letters addressed to the exchanges.

Regulatory Framework

The certificate submission follows SEBI guidelines referenced in circulars NSDL/CIR/II/5/2019 and CDSL/OPS/RTA/POLICY/2019/14, both dated January 25, 2019. These regulations ensure transparency in the dematerialization process and maintain accurate records of securities transactions.

This routine compliance filing demonstrates Indo Us Bio-Tech Limited's commitment to maintaining regulatory standards and transparent reporting practices as required by Indian securities regulations.